What does the rest of 2020 have in store for pharma M&A?

Michael Jewell, partner and head of healthcare and life sciences at Cavendish Corporate Finance, considers how four key trends look set to continue to shape the industry in an Expert View piece.

As 2019 came to a close, it was clear that the end of the second decade of the 21st century had been a bumper time for M&A activity across the global pharmaceutical sector.

Indeed, taking a wider view across the last five years, we can see how there were more than 400 M&As globally in just the gene therapy, immuno-oncology, microbiome, and orphan drugs therapeutic categories.